International Blog

i6000 – the workhorse of a pathology lab! - (Interface for both clinical and research diagnostics)

When it comes to cancer diagnostics, tissue-based staining is still the gold standard of diagnostic workflow. And when there are thousands of cancer patients – worldwide - waiting eagerly for “their life and death question”, there is no luxury of time! Everyday there could be hundreds of samples waiting to be tested – and so some form of automation and high-throughput becomes mandatory.

Enter the semi-automatic workhorse of cancer diagnostics – the BioGenex i6000TM system. The BioGenex i6000 Elite Dx is a semi-automated, high-throughput, multiplex IHC system that is flexible, efficient and value for the bucks!

Read More

Xmatrx® Elite – All-in-One & All-at-Once complete workflow solution! - For Your Tissue Diagnostics Needs!!

High-throughput and automation are the keywords in any cancer diagnostic lab – our Xmatrx® series are just that and more! Xmatrx Elite is versatile for any slide-based staining – IHC, ISH, FISH, multiplex IHC, in situ PCR, micro-RNA, and special staining (SS). Crisp and reliable staining result! Everytime!


Read More

EZ-AR2 Elegance – All-in-One and All-at-Once Antigen Retrieval solution

Antigen Retrieval:

Antigen retrieval is an effective method of unmasking antigenic epitopes on the surface of formalin-fixed paraffin-embedded (FFPE) tissue sections. The antigen retrieval technique breaks the methylene bridges between epitopes and unrelated proteins to expose antigenic sites for antibody binding (1). BioGenex Laboratories Inc. invented the reverse epitope masking method in 1991 (2), with this assay now being routinely practiced in laboratories throughout the world. For in-depth article on Antigen Retrieval click here.

EZ-AR2 Elegance Antigen Retrieval Solution:

BioGenex EZ-AR2 Elegance is the first universal one-step solution for preparation of formalin-fixed paraffin-embedded (FFPE) tissue sections for IHC staining. The high throughput system is designed to perform de-wax, rehydration, and antigen retrieval all in one simple step. EZ-AR2 Elegance buffer together with EZ-Retriever® processes about 100 slides in less than 30 minutes. Efficient antigen retrieval allows higher dilution of antibodies and shortens incubation times for many antibodies – cost-effective and saves time!

Read More

EZ-Retriever® + EZ-AR™ Elegance solution - Features and Benefits

EZ-Retriever® System:


Antigen Retrieval
- invented by BioGenex - is an effective method of unmasking antigenic epitopes in formalin-fixed paraffin-embedded tissue sections (FFPE) by heating in microwave using specially formulated Antigen Retrieval solutions. The Antigen Retrieval technique breaks the formalin induced cross-linking of proteins, allowing access of antigenic epitopes. Covered by patents issued to BioGenex, this method has been practiced in laboratories throughout the world.

Read More

Best for IHC Staining in an Independent Assessment - BioGenex US

The Synaptophysin (SYN) gene is located on the short arm of the X chromosome. Mutations in this gene are associated with X-linked mental retardation (XLMR). The SYN gene product is a 38 kD glycoprotein that is localized to the membrane of synaptic vesicles. Using immunohistochemistry, synaptophysin can be identified in a range of neural and neuroendocrine tissues, including neurons of the central nervous system, cells of the adrenal medulla, thyroid and pancreatic islets. As a specific marker for these tissues, it can be used to identify tumors originating from them, such as neuroblastoma, retinoblastoma, phaeochromocytoma, carcinoid, small-cell carcinoma, medulloblastoma and medullary thyroid carcinoma.

Read More

CDX2 to identify Colon Cancer patients - BioGenex International

May 12, 2016

Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the United States. In 2016 about 140,000 people will be diagnosed and 50,000 will die from this disease. On average, the lifetime risk of developing colon cancer is about 5%, however, this varies widely according to individual risk factors. About 72% of cases arise in the colon and about 28% in the rectum. In recent years, introduction of a new adjuvant chemotherapy for patients with stage III colon cancer, was very successful and significantly increased disease-free survival in these patients. However, there was no improvement in disease-free survival for patients with earlier-stage (stage I and II) disease due to the lack of simple, reliable criteria for the identification of patients who are at high risk for relapse. Now, a groundbreaking study published in the New England Journal of Medicine, demonstrated that CDX2 antibodies from BioGenex (Clone CDX2-88) can be employed in a new prognostic approach and help save lives of stage II Colon Cancer patients.

Read More

Innovation Protects for Earth Day 2016 - BioGenex International

Apr 22, 2016

 

BioGenex has a rich history of innovation in the field of Immunohistochemistry (IHC) and In situ Hybridization (ISH) and a strong intellectual portfolio, consisting of several US and foreign-issued patents, which not only revolutionize precision medicine but also support the environment by promoting the use of Green non-toxic reagents and reducing toxic waste and include:

Read More

New Treatment for Urothelial Cancer - BioGenex International

Apr 21, 2016

Urothelial Carcinoma (UCC, also known as transitional cell carcinoma) is a cancer that starts in the urothelial cells, which line the inside of the bladder and other parts of the urinary tract. According to the American Cancer Society there were over 76,000 new cases of bladder cancer diagnosed and over 15,000 deaths from advanced bladder cancer in the United States in 2014. At stage I, the 5-year survival rate is about 88% but at stage IV, the 5-year survival rate falls to 15%. Poor prognosis and ineffective therapies for patients with advanced bladder cancer make the discovery of new drugs very important for the treatment of this common disease.

In a pioneering study published last month in Molecular Cancer Therapeutics, researchers at Agensys Inc. identified the SLITRK6 protein as a new UCC biomarker and developed a novel antibody-drug conjugate (ADC) targeting SLITRK6 for the treatment of metastatic bladder cancer. Recent advances in the antibody-drug conjugate (ADC) technology and two recently approved ADCs have brought this drug class to the forefront of drug development in oncology.

Read More

BioGenex | Micrographic Surgery for Invasive Melanomas

Mar 22, 2016

 

Anti-Melan-A, Clone A103

 

 

The incidence of melanoma, the most deadly form of skin cancer, has doubled in the past 40 years. Globally, in 2012, melanoma occurred in 232,000 people and resulted in 55,000 deaths. In 2016, it is estimated that there will be 76,380 new cases of melanoma in the United States and 10,130 deaths from the disease. If melanoma is diagnosed and treated early, it is typically curable, but if it is not, melanoma becomes hard to treat and is often fatal.

Read More

Subscribe to Blog

Recent Posts